financetom
Business
financetom
/
Business
/
Why SolarEdge Technologies (SEDG) Stock Is Falling
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why SolarEdge Technologies (SEDG) Stock Is Falling
Oct 10, 2024 11:24 PM

SolarEdge Technologies Inc ( SEDG ) saw its shares fall Thursday afternoon by 5.47% to $17.96, amid a sector-wide decline in clean energy stocks, after a price target reduction for First Solar ( FSLR ) sparked broader concerns about the solar energy industry.

What Happened: Thursday’s decline began after Jefferies analyst Dushyant Ailani cut the price target for First Solar ( FSLR ) from $271 to $266, marking the second reduction in a week following B of A Securities' move to lower its target from $343 to $321 earlier.

Although First Solar's ( FSLR ) downgrade was specific to the company's valuation, the ripple effects quickly spread across the solar sector, including SolarEdge ( SEDG ), a key player in solar inverters and power optimization technologies.

Read Also: Tech, Consumer Discretionary Stocks Fall, Utilities Sector Outperforms On Surprisingly High Inflation, Jobless Claims Data

While SolarEdge ( SEDG ) doesn't compete directly with First Solar ( FSLR ) in solar panel manufacturing, the fortunes of both companies are closely tied to overall demand in the solar market.

A slowdown in growth or pricing pressure in the solar panel space could have downstream effects on SolarEdge's ( SEDG ) business, which relies on robust panel installations to fuel demand for its products.

What Else: As one of the world's largest providers of inverter and energy management solutions, SolarEdge ( SEDG ) plays a critical role in enabling the efficient conversion of solar energy to usable electricity.

When negative signals emerge from the solar industry, such as the lowered price target for First Solar ( FSLR ), it raises concerns about demand for SolarEdge's ( SEDG ) products, especially as it faces growing competition from domestic and international players.

If panel prices fall or installation volumes slow, SolarEdge ( SEDG ) could experience reduced demand for its power conversion and monitoring systems, impacting future growth prospects.

Read Also: How To Watch Tesla Robotaxi Day Live: Elon Musk’s Autonomous Vehicle Event Is Here

What To Watch For: In addition to industry-specific factors, broader economic concerns have cast a shadow over SolarEdge ( SEDG ) and the renewable energy sector. Thursday's Consumer Price Index (CPI) report for September revealed higher-than-expected inflation, alongside a surprise uptick in weekly jobless claims.

This combination of data has reignited fears that the Federal Reserve may need to maintain elevated interest rates for a longer period. For SolarEdge ( SEDG ), whose business model depends on large-scale, capital-intensive solar installations, the prospect of sustained higher interest rates could dampen demand as financing costs rise.

This would make it more expensive for customers, including homeowners and businesses, to fund solar installations, which are often partially financed through loans or other credit instruments.

Read Also: Hurricane Milton Closes Multiple Florida Airports, Over 3,000 Flights Canceled And Delayed: 10 Airline Stocks That Could Be Hit Hardest

How To Buy SEDG Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in SolarEdge Technologies’ case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

According to data from Benzinga Pro, SEDG has a 52-week high of $130.38 and a 52-week low of $17.12.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
CAVA Group Fiscal Q2 Earnings Fall, Revenue Rises
CAVA Group Fiscal Q2 Earnings Fall, Revenue Rises
Aug 29, 2024
04:29 PM EDT, 08/22/2024 (MT Newswires) -- CAVA Group ( CAVA ) reported fiscal Q2 earnings late Thursday of $0.17 per diluted share, down from $0.21 a year ago. Analysts polled by Capital IQ expected earnings of $0.12. Revenue for the quarter that ended July 14 was $233.5 million, up from $172.9 million a year earlier. Analysts surveyed by Capital...
--Belden Keeps Quarterly Dividend at $0.05 a Share, Payable on Oct. 8 to Shareholders on Sept. 12
--Belden Keeps Quarterly Dividend at $0.05 a Share, Payable on Oct. 8 to Shareholders on Sept. 12
Aug 29, 2024
04:29 PM EDT, 08/22/2024 (MT Newswires) -- Price: 103.50, Change: -0.58, Percent Change: -0.56 ...
Infineon agrees to pay $837 mln to settle Qimonda dispute
Infineon agrees to pay $837 mln to settle Qimonda dispute
Aug 29, 2024
Aug 22 (Reuters) - German chipmaker Infineon Technologies AG said on Thursday it has reached a settlement with Qimonda AG's insolvency administrator by agreeing to pay 753.5 million euros ($837.21 million), ending the long-pending legal dispute. Qimonda's administrator had sued Infineon in 2010 for 3.35 billion euros, arguing the chipmaker had transferred operations to it at an inflated price. The...
Bristol-Myers Squibb-backed Zenas BioPharma files for US IPO
Bristol-Myers Squibb-backed Zenas BioPharma files for US IPO
Aug 29, 2024
Aug 22 (Reuters) - Bristol-Myers Squibb ( BMY )-backed Zenas BioPharma has filed to go public in the United States, a regulatory filing showed on Thursday, underscoring improving investor appetite for new listings. The U.S. initial public offering market is in the early innings of a recovery on hopes of potential interest-rate cuts and lower market volatility. Zenas BioPharma, an...
Copyright 2023-2026 - www.financetom.com All Rights Reserved